Oncology

News

Update: Daiichi Sankyo says Plexxikon R&D unit will close do...

Just over a decade after being acquired by Daiichi Sankyo, US biotech Plexxikon will be shuttered at the end of March, with its R&D

News

BMS cuts $3.15bn deal with Century for cancer cell therapies

Bristol-Myers Squibb chief executive Giovanni Caforio has promised to invest in the company's pipeline at the virtual JP Morgan Healthcare Conference, and demonstrated that commitment by li

News

Blue Note leukaemia DTx gets FDA breakthrough tag

A prescription digital therapeutic (DTx) for leukaemia patients developed by Blue Note Therapeutics has been awarded breakthrough device status by the FDA.

News

Amgen grabs EU approval for pathfinder KRAS drug Lumykras

Amgen now has regulatory approval on both sides of the Atlantic for Lumykras, the culmination of many years of effort to bring a drug to market that inhibits KRAS – a cancer target that for

News

Another big AI deal as Sanofi taps Exscientia for 15 new dru...

If the last couple of days is an indication, 2022 is already shaping up to be the year of big-ticket alliances between big pharma companies and specialists in artificial intelligence-driven

News

Roivant joins RNA splicing push with Eisai deal

Roivant is the latest pharma group to take a position in the emerging field of therapies targeted at RNA splicing, licensing exclusive rights to a drug developed by a unit of Japanese drugm

Update: Daiichi Sankyo says Plexxikon R&D unit will close do...

BMS cuts $3.15bn deal with Century for cancer cell therapies

Blue Note leukaemia DTx gets FDA breakthrough tag

Amgen grabs EU approval for pathfinder KRAS drug Lumykras

Another big AI deal as Sanofi taps Exscientia for 15 new dru...

Roivant joins RNA splicing push with Eisai deal

Bankruptcy threat looms as Quince runs out of options

How to meet your physicians where they are online

Oncology

Editor's Picks